Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: Report of two cases and review of the literature

Narra, Kalyani; Borghaei, Hossein; Al‐Saleem, Tahseen; Höglund, Mattias; Smith, Mitchell R.

doi:10.1016/j.leukres.2005.05.017

Cited by 39 publications

(33 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[16][17][18] and pure red cell aplasia (PRCA). 19 The occurrence of immune cytopenia has been reported to range from less than 5% to 38%. 14,20 In the most recent studies, the proportion of patients presenting with autoimmune cytopenia at some point during the course of their disease ranges from 4.3% to 9.7%.…”

Section: Epidemiologymentioning

confidence: 99%

Chronic lymphocytic leukemia and autoimmunity: a systematic review

Hodgson¹,

Ferrer²,

Montserrat³

et al. 2011

Haematologica

120

View full text Add to dashboard Cite

Section: Epidemiologymentioning

confidence: 99%

Chronic lymphocytic leukemia and autoimmunity: a systematic review

Hodgson¹,

Ferrer²,

Montserrat³

et al. 2011

Haematologica

120

View full text Add to dashboard Cite

“…Both patients responded dramatically to rituximab therapy in a short period of time and became transfusion-independent [15]. Rituximab was used later by others for the treatment of PRCA in CLL, and the results were promising [16,17]. Okamoto et al [18] reported on the first patient with CD5À CLL associated with OIT who was successfully treated by rituximab.…”

Section: Discussionmentioning

confidence: 99%

The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia

et al. 2006

View full text Add to dashboard Cite

The most frequent autoimmune complication in chronic lymphocytic leukemia (CLL) is autoimmune hemolytic anemia (AIHA). There are various treatment modalities; however, there is not much experience with the use of the chimeric anti-CD20 monoclonal antibody rituximab in the autoimmune complications of CLL. Here, we present our patient with CLL and AIHA whose AIHA was unresponsive to various treatment modalities. The administration of 375 mg/m 2 /day rituximab weekly for four cycles halted hemolysis and resulted in resolution of the patient's anemia. One year after therapy, the patient is well with a normal blood count. Rituximab might be preferred over other treatment modalities in the autoimmune complications of CLL because it is effective and has fewer side effects than other therapies. Am. J.

show abstract

“…To date, the efficacy of CS, CY and CsA for patients with primary or secondary PRCA has been reported to be between 30 and 62, 7 and 20, 65 and 87 %, respectively [4] (Table 1). More recently, the efficacies of the anti-CD20 monoclonal antibody, rituximab, and anti-CD52 monoclonal antibody, alemtuzumab to induce remissions of therapy-resistant PRCA have also been reported [5,6].…”

Section: Discussionmentioning

confidence: 99%